WuXi XDC Reports Impressive Growth in 2025, Solidifying Its Position in Bioconjugate CRDMO Market
In 2025, WuXi XDC Cayman Inc., a prominent Contract Research, Development, and Manufacturing Organization (CRDMO) in the bioconjugate sector, reported remarkable financial performance, reaffirming its leading status in the industry. The company experienced a staggering 46.7% year-over-year (YoY) increase in revenue, reaching RMB 5,944 million. This robust growth can be attributed to the rising customer base and the successful development of projects in the rapidly evolving global Antibody-Drug Conjugate (ADC) and bioconjugate markets.
The gross profit surged by 72.5% compared to the previous year, totaling RMB 2,139 million, reflecting a gross margin of 36.0%, which is a significant improvement of 5.4 percentage points from 2024. Furthermore, WuXi XDC reported an impressive adjusted net profit of RMB 1,559 million, representing an increase of 69.9% YoY and a net profit margin of 26.2%, up 3.6 percentage points from the previous year.
An exceptional customer growth strategy saw WuXi XDC expand its global client list to over 640 companies, securing partnerships with 14 out of the top 20 pharmaceutical companies worldwide. The company successfully engaged in 252 integrated contract manufacturing projects (iCMC projects), with 70 new projects signed in 2025. Additionally, WuXi XDC's pipeline for Product Process Qualification (PPQ) projects saw growth, with 18 projects secured, including 10 new ones added in the same year. This contributed to a total backlog of US$1.49 billion, showcasing a robust 50.3% growth YoY.
In terms of strategic initiatives, WuXi XDC advanced two main mergers and acquisitions that enhanced its operational capabilities and expanded its reach. The acquisition of BioDlink improved the company’s integrated bioconjugate production capabilities, while the acquisition of a site in Hefei boosted expertise in peptide and oligonucleotide synthesis.
Technologically, WuXi XDC continuously invests in research and development. Breakthrough advancements across the WuXiDARx™, X-LinC, and WuXiTecan platforms demonstrate the company's commitment to innovation in developing next-generation bioconjugates.
The WuXiDARx™ technology allows for streamlined production of dual-payload ADCs, enabling enhanced drug efficacy through high homogeneity levels at clinical settings. The newly launched WuXiTecan-1 and WuXiTecan-2 platforms are designed to improve stability and hydrophilicity of the drug linkers, demonstrating excellent preclinical safety and efficacy profiles. As WuXi XDC transitions into 2026, it aims to expand its groundbreaking research and product offerings further.
CEO Dr. Jimmy Li emphasized the transformative nature of 2025, marking it as a pivotal year for the company. With substantial investments and strategic collaborations, such as the recent partnership with Earendil Labs regarding the WuXiTecan-2 payload-linker technology, WuXi XDC is positioned for sustained growth and innovation in the rapidly evolving bioconjugate landscape. As 2026 unfolds, WuXi XDC is poised to leverage its global supply chain and partner with clients to deliver groundbreaking therapies worldwide, cementing its leadership role in the bioconjugate CRDMO market.
The gross profit surged by 72.5% compared to the previous year, totaling RMB 2,139 million, reflecting a gross margin of 36.0%, which is a significant improvement of 5.4 percentage points from 2024. Furthermore, WuXi XDC reported an impressive adjusted net profit of RMB 1,559 million, representing an increase of 69.9% YoY and a net profit margin of 26.2%, up 3.6 percentage points from the previous year.
An exceptional customer growth strategy saw WuXi XDC expand its global client list to over 640 companies, securing partnerships with 14 out of the top 20 pharmaceutical companies worldwide. The company successfully engaged in 252 integrated contract manufacturing projects (iCMC projects), with 70 new projects signed in 2025. Additionally, WuXi XDC's pipeline for Product Process Qualification (PPQ) projects saw growth, with 18 projects secured, including 10 new ones added in the same year. This contributed to a total backlog of US$1.49 billion, showcasing a robust 50.3% growth YoY.
In terms of strategic initiatives, WuXi XDC advanced two main mergers and acquisitions that enhanced its operational capabilities and expanded its reach. The acquisition of BioDlink improved the company’s integrated bioconjugate production capabilities, while the acquisition of a site in Hefei boosted expertise in peptide and oligonucleotide synthesis.
Technologically, WuXi XDC continuously invests in research and development. Breakthrough advancements across the WuXiDARx™, X-LinC, and WuXiTecan platforms demonstrate the company's commitment to innovation in developing next-generation bioconjugates.
The WuXiDARx™ technology allows for streamlined production of dual-payload ADCs, enabling enhanced drug efficacy through high homogeneity levels at clinical settings. The newly launched WuXiTecan-1 and WuXiTecan-2 platforms are designed to improve stability and hydrophilicity of the drug linkers, demonstrating excellent preclinical safety and efficacy profiles. As WuXi XDC transitions into 2026, it aims to expand its groundbreaking research and product offerings further.
CEO Dr. Jimmy Li emphasized the transformative nature of 2025, marking it as a pivotal year for the company. With substantial investments and strategic collaborations, such as the recent partnership with Earendil Labs regarding the WuXiTecan-2 payload-linker technology, WuXi XDC is positioned for sustained growth and innovation in the rapidly evolving bioconjugate landscape. As 2026 unfolds, WuXi XDC is poised to leverage its global supply chain and partner with clients to deliver groundbreaking therapies worldwide, cementing its leadership role in the bioconjugate CRDMO market.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.